The Lexington, MA-based company has enrolled the first patient in a pivotal study of its Revita DMR treatment. Fractyl said Revita uses thermal ablation to ablate a portion of the duodenum mucosa, which if proven, could improve glucose control in patients struggling to manage the disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,